ReviewChest2017
The Role of Infection in Interstitial Lung Diseases: A Review.
Review in Chest, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- The impact of air pollution on interstitial lung disease: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Pre-existing interstitial lung disease in patients with coronavirus disease 2019: A meta-analysis.International immunopharmacology · 2021Pooled it
- The Role of Herpes Viruses in Pulmonary Fibrosis.Frontiers in medicine · 2021Pooled it
- Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.Frontiers in immunology · 2026Trial
- Telomere-associated non-malignant pulmonary diseases: Pathogenic mechanisms and therapeutic strategies.Acta pharmaceutica Sinica. B · 2026Review
- Vaccinations in patients with interstitial lung diseases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Targeting mTORC1/TGFB1 signaling with a novel Bergapten-Esculetin combination: a computational and experimental approach in idiopathic pulmonary fibrosis.Molecular diversity · 2026Article
- Real-world evidence on hospitalization, infection, and vascular outcomes among interstitial lung disease subtypes.Respiratory medicine and research · 2026Article
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Interstitial lung disease in systemic sclerosis-a retrospective cross-sectional study in Taiwan.Clinical rheumatology · 2026Article
- Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature.Journal of clinical medicine · 2026Review
- Prevalence and outcomes of SARS-CoV-2 infection in ILD: Post-pandemic study in South Italy.Multidisciplinary respiratory medicine · 2026Article
- Cognitive dysfunction in patients with interstitial lung disease.Frontiers in medicine · 2026Article
- Computed tomography imaging features of major pulmonary and extrapulmonary complications of fibrotic lung diseases.Einstein (Sao Paulo, Brazil) · 2026Review
- The Clinical Features and Prognosis of Idiopathic and Infection-Triggered Acute Exacerbation of Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2025Article
- Global disease burden of interstitial lung disease and pulmonary sarcoidosis, 1990-2021, and forecast analysis over the next decade.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Trends in interstitial lung disease and the COVID-19 pandemic in the United States from 1999 to 2022.Respiratory research · 2025Article
- Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease.The clinical respiratory journal · 2025Review
- Spatial phenotyping of human bronchial airways in obstructive lung disease.Respiratory research · 2025Article
- Air pollution and alveolar health.European respiratory review : an official journal of the European Respiratory Society · 2025Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byResponse.2017
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) comprises an array of heterogeneous parenchymal lung diseases that are associated with a spectrum of pathologic, radiologic, and clinical manifestations. There are ILDs with known causes and those that are idiopathic, making treatment strategies challenging. Prognosis can vary according to the type of ILD, but many exhibit gradual progression with an unpredictable clinical course in individual patients, as seen in idiopathic pulmonary fibrosis and the phenomenon of "acute exacerbation"(AE). Given the often poor prognosis of these patients, the search for a reversible cause of respiratory worsening remains paramount. Infections have been theorized to play a role in ILDs, both in the pathogenesis of ILD and as potential triggers of AE. Research efforts thus far have shown the highest association with viral pathogens; however, fungal and bacterial organisms have also been implicated. This review aims to summarize the current knowledge on the role of infections in the setting of ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.